Two months after going public, Medpace Holdings Inc. has big expansion plans that call for the hiring of 650 additional employees and retain more than 1,150 positions, the Cincinnati Business Courier reported.
In 3Q Report, Shire Breaks Out Data From Baxalta Acquisition and Announces Several Program Terminations
Third-quarter financial reports show how companies are doing going into the end of the year. And this year, at least, they show a number of biopharma companies killing programs. Shire reported that it was terminating its SHP610 program for Sanfilippo A after a failed Phase IIb study.
Pfizer has abandoned its PCSK9 inhibitor program to treat cholesterol. The company is ending its global development of all bococizumab SPIRE Phase III trials.
Although they have both been out from their executive leadership roles at embattled Valeant Pharmaceuticals, J. Michael Pearson and Howard Schiller’s troubles are not over. Both men may be facing a criminal investigation probe by U.S. prosecutors, according to news reports.
The U.S. FDA gave fast-track review status to Novartis’ medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer.